JP2021521267A5 - - Google Patents
Info
- Publication number
- JP2021521267A5 JP2021521267A5 JP2021501072A JP2021501072A JP2021521267A5 JP 2021521267 A5 JP2021521267 A5 JP 2021521267A5 JP 2021501072 A JP2021501072 A JP 2021501072A JP 2021501072 A JP2021501072 A JP 2021501072A JP 2021521267 A5 JP2021521267 A5 JP 2021521267A5
- Authority
- JP
- Japan
- Prior art keywords
- hvr
- amino acid
- acid sequence
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/081096 | 2018-03-29 | ||
| CN2018081096 | 2018-03-29 | ||
| PCT/CN2019/080496 WO2019185035A1 (en) | 2018-03-29 | 2019-03-29 | Anti-pd-l1 antibodies and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521267A JP2021521267A (ja) | 2021-08-26 |
| JP2021521267A5 true JP2021521267A5 (enExample) | 2022-04-06 |
| JP7433285B2 JP7433285B2 (ja) | 2024-02-19 |
Family
ID=68060953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021501072A Active JP7433285B2 (ja) | 2018-03-29 | 2019-03-29 | 抗ｐｄ－ｌ１抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12054548B2 (enExample) |
| EP (1) | EP3774920A4 (enExample) |
| JP (1) | JP7433285B2 (enExample) |
| KR (1) | KR20210016514A (enExample) |
| CN (2) | CN112424225B (enExample) |
| AU (1) | AU2019241345A1 (enExample) |
| CA (1) | CA3095076A1 (enExample) |
| MY (1) | MY204733A (enExample) |
| WO (1) | WO2019185035A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3187850A1 (en) * | 2020-08-04 | 2022-02-10 | Bryan Glaser | Pd-l1 binding agents and uses thereof |
| WO2022177393A1 (ko) * | 2021-02-19 | 2022-08-25 | (주)샤페론 | Pd-l1에 대한 단일 도메인 항체 및 이의 용도 |
| CN114225023B (zh) * | 2021-12-22 | 2022-10-18 | 宝船生物医药科技(上海)有限公司 | 抗csf-1r抗体联合抗pd-l1抗体的应用 |
| WO2023193239A1 (en) | 2022-04-08 | 2023-10-12 | Peter Peizhi Luo | Anti-cd28 antibodies and methods of use thereof |
| WO2024107731A2 (en) * | 2022-11-14 | 2024-05-23 | Ablexis, Llc | Anti-pd-l1 antibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2612241C (en) * | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| WO2016061142A1 (en) * | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| RU2766890C2 (ru) | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| EP4086285A1 (en) * | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
| US10059769B2 (en) * | 2016-06-13 | 2018-08-28 | I-Mab | Anti-PD-L1 antibodies and uses thereof |
| RU2766582C2 (ru) * | 2016-12-23 | 2022-03-15 | Ремд Биотерапьютикс, Инк. | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) |
-
2019
- 2019-03-29 CN CN201980023860.8A patent/CN112424225B/zh active Active
- 2019-03-29 US US17/043,454 patent/US12054548B2/en active Active
- 2019-03-29 CA CA3095076A patent/CA3095076A1/en active Pending
- 2019-03-29 EP EP19778308.7A patent/EP3774920A4/en not_active Withdrawn
- 2019-03-29 AU AU2019241345A patent/AU2019241345A1/en not_active Abandoned
- 2019-03-29 MY MYPI2020005109A patent/MY204733A/en unknown
- 2019-03-29 KR KR1020207030994A patent/KR20210016514A/ko active Pending
- 2019-03-29 CN CN202310883785.0A patent/CN117362436A/zh active Pending
- 2019-03-29 JP JP2021501072A patent/JP7433285B2/ja active Active
- 2019-03-29 WO PCT/CN2019/080496 patent/WO2019185035A1/en not_active Ceased